Compounds originating from the edible mushroom Auricularia auricula-judae inhibit tropomyosin receptor kinase B activity

Orr Shahar; Idan Pereman; Hazem Khamisie; Nirit Ezov; Ofer Danay; Ali Khattib; Ron Schweitzer; Soliman Khatib; Jamal Mahajna

doi:10.1016/j.heliyon.2023.e13756

Compounds originating from the edible mushroom Auricularia auricula-judae inhibit tropomyosin receptor kinase B activity

Heliyon. 2023 Feb 16;9(3):e13756. doi: 10.1016/j.heliyon.2023.e13756. eCollection 2023 Mar.

Authors

Orr Shahar^{1

2}, Idan Pereman^{1

2}, Hazem Khamisie¹, Nirit Ezov¹, Ofer Danay^{1

2}, Ali Khattib¹, Ron Schweitzer^{1

3}, Soliman Khatib^{1

3}, Jamal Mahajna^{1

2}

Affiliations

¹ Department of Nutrition and Natural Products, Migal - Galilee Research Institute, Kiryat Shmona, Israel.
² Department of Biotechnology, Tel Hai College, Kiryat Shmona, Israel.
³ Analytical Laboratory, Tel Hai College, Kiryat Shmona, Israel.

Abstract

Tropomyosin receptor kinase B (TrkB) serves as a pivotal factor in various cancers. To identify novel natural compounds with TrkB-inhibiting properties, a screening approach was applied using extracts from a collection of wild and cultivated mushroom fruiting bodies, and Ba/F3 cells that ectopically express TrkB (TPR-TrkB). We selected mushroom extracts that selectively inhibited proliferation of the TPR-TrkB cells. We then evaluated the ability of exogenous interleukin 3 to rescue growth inhibition by the selected TrkB-positive extracts. An ethyl acetate extract of Auricularia auricula-judae actively inhibited auto-phosphorylation of TrkB. LC-MS/MS analysis of this extract revealed substances that might be responsible for the observed activity. This screening approach demonstrates, for the first time, that extracts originating from the mushroom A. auricula-judae exhibit TrkB-inhibition properties that might hold therapeutic potential for TrkB-positive cancers.

Keywords: Auricularia auricula-Judae mushroom; Cancer; Kinase inhibition; Tropomyosin receptor kinase B (TrkB).